The best characterized biological mechanisms of venetoclax resistance in CLL/SLL are acquisition of BCL2 resistance mutations and upregulation of alternative pro-survival proteins such as BCL-XL and MCL1. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.